Avtor/Urednik		Vlaisavljević, Veljko; Meden-Vrtovec, Helena; Lewandowski, Piotr; Radwan, Michał; Langerova, Alena; Vicena, Milan; Války, Jozef; Herman, Miroslav; Usoniené, Audroné; Treijs, Gints
Naslov		An observational study of assisted reproductive technology outcomes in new European Union member states: an overview of protocols used for ovarian stimulation
Tip		članek
Vir		CURR MED RES OPIN
Vol. in št.		Letnik 26, št. 4
Leto izdaje		2010
Obseg		str. 819-825
Jezik		eng
Abstrakt		Background: The development of new fertility treatment options has facilitated individualized assisted reproductive technology (ART) protocols to improve outcomes. Manufacturing improvements to recombinant human follitropin alfa have allowed precise dosing based on mass (filled-by-mass; FbM) rather than bioactivity (filled-by-bioassay; FbIU). Continued monitoring and reporting of follitropin alfa treatment outcomes in routine clinical practice is essential. Objective: To provide an overview of the frequency of different controlled ovarian-stimulation protocols used in in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles in new European Union member states, and to provide post-registration efficacy and safety data on follitropin alfa. Research design and methods: A 2-year, prospective, observational, multicentre, Phase IV study conducted at ART clinics in the Czech Republic, Estonia, Latvia, Lithuania, Poland, Slovakia and Slovenia. Women aged 18-47 years undergoing ovarian stimulation with follitropin alfa for conventional IVF or ICSI were eligible for inclusion. The main treatment outcome was cumulative clinical pregnancy rate. Data were analysed descriptively. RESULTS: Clinical pregnancy outcomes were available for 4055 of 4085 (99.3%) patients. In total, 1897 (46.8%) patients used follitropin alfa FbIU; 2133 (52.6%) used follitropin alfa FbM. Clinical pregnancy was achieved by 39.5% (1603/4055) of patients. A greater proportion of patients with polycystic ovary syndrome achieved a clinical pregnancy than those with endometriosis (41.8% vs 37.8%, respectively). A higher cumulative pregnancy rate was observed with the use of follitropin alfa FbM than follitropin alfa FbIU (41.3% vs 37.8%, respectively; p = 0.02). Conclusions: This study represents the most comprehensive audit of individualized ART in clinical practice in Central and Eastern Europe. Overall, clinical pregnancy was achieved by 39. (Abs. trunc. at 2000 ch.)
Deskriptorji		OVULATION INDUCTION TREATMENT OUTCOME PREGNANCY RATE